MannKind Co. (MNKD) Upgraded to “Buy” at Griffin Securities
Jan 6, 2016 16:50:12 GMT -5
bioexec25, inittowinit, and 2 more like this
Post by sla55 on Jan 6, 2016 16:50:12 GMT -5
zolmax.com/investing/mannkind-co-mnkd-upgraded-to-buy-at-griffin-securities/288788/
MannKind Co. (NASDAQ:MNKD) was upgraded by stock analysts at Griffin Securities to a “buy” rating in a research report issued on Wednesday, Marketbeat reports. The firm currently has a $4.00 price target on the biopharmaceutical company’s stock. Griffin Securities’ price objective suggests a potential upside of 435.05% from the company’s current price.
Shares of MannKind (NASDAQ:MNKD) opened at 0.7476 on Wednesday. The stock’s market cap is $305.97 million. MannKind has a one year low of $0.70 and a one year high of $7.88. The company has a 50-day moving average of $1.77 and a 200 day moving average of $3.45.
MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. During the same quarter last year, the company posted ($0.09) EPS. On average, analysts predict that MannKind will post ($0.28) earnings per share for the current year.
Several other equities research analysts have also commented on MNKD. Piper Jaffray lowered shares of MannKind from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $4.00 to $1.50 in a report on Wednesday, September 9th. Zacks Investment Research upgraded shares of MannKind from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Tuesday, September 29th. Vetr lowered shares of MannKind from a “strong-buy” rating to a “buy” rating and set a $3.38 price target for the company. in a report on Monday, October 12th. RBC Capital lowered shares of MannKind from an “outperform” rating to an “underperform” rating and reduced their price target for the company from $9.00 to $1.00 in a report on Wednesday, November 4th. Finally, Goldman Sachs reiterated a “sell” rating on shares of MannKind in a research note on Sunday, November 8th. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.14.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company’s product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.
MannKind Co. (NASDAQ:MNKD) was upgraded by stock analysts at Griffin Securities to a “buy” rating in a research report issued on Wednesday, Marketbeat reports. The firm currently has a $4.00 price target on the biopharmaceutical company’s stock. Griffin Securities’ price objective suggests a potential upside of 435.05% from the company’s current price.
Shares of MannKind (NASDAQ:MNKD) opened at 0.7476 on Wednesday. The stock’s market cap is $305.97 million. MannKind has a one year low of $0.70 and a one year high of $7.88. The company has a 50-day moving average of $1.77 and a 200 day moving average of $3.45.
MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. During the same quarter last year, the company posted ($0.09) EPS. On average, analysts predict that MannKind will post ($0.28) earnings per share for the current year.
Several other equities research analysts have also commented on MNKD. Piper Jaffray lowered shares of MannKind from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $4.00 to $1.50 in a report on Wednesday, September 9th. Zacks Investment Research upgraded shares of MannKind from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Tuesday, September 29th. Vetr lowered shares of MannKind from a “strong-buy” rating to a “buy” rating and set a $3.38 price target for the company. in a report on Monday, October 12th. RBC Capital lowered shares of MannKind from an “outperform” rating to an “underperform” rating and reduced their price target for the company from $9.00 to $1.00 in a report on Wednesday, November 4th. Finally, Goldman Sachs reiterated a “sell” rating on shares of MannKind in a research note on Sunday, November 8th. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.14.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company’s product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.
